Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

More and more people are talking about Novartis over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $112.13? Only time will tell. The information below will give you a ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Can the Carcinoid Market Maintain its Impressive Growth Momentum? The exponential growth witnessed in the carcinoid tumor market is only the tip of the iceberg with predictions estimating that the ...